100% SVR Demonstrated in Combination With Sovaprevir, NS3/4A Protease Inhibitor, in Late Breaker Oral Presentation

NEW HAVEN, CT, USA I March 14, 2014 I Achillion Pharmaceuticals, Inc. (ACHN) today announced that two oral presentations were made at the 23rd Asian Pacific Association for the Study of the Liver (APASL) Conference 2014 in Brisbane, Australia. Updated Phase 2 clinical trial results evaluating a 150 mg loading dose followed by 50 mg once daily of ACH-3102 in combination with either once daily 200 mg or 400 mg of sovaprevir and twice daily ribavirin showed that 100% of patients achieved SVR12 (n=8) including subjects who had Y93 mutations at baseline. A second oral presentation on ACH-3102 was made at APASL 2014 that discussed clinical virology and the lack of virologic breakthrough that was observed in the novel Phase 2 clinical trial evaluating ACH-3102 with ribavirin for patients with treatment-naive genotype 1b HCV. Despite the presence of up to six linked mutations identified at baseline in the NS5A protein, ACH-3102, without the co-administration of interferon or a second direct-acting antiviral, was able to suppress viral replication with no virologic breakthrough observed during 12 weeks of treatment.

Dr. David Apelian, M.D., Ph.D., Chief Medical Officer of Achillion, commented, “The safety, tolerability, high barrier to resistance, and clinical activity observed in these two Phase 2 trials continue to support the differentiated profile of ACH-3102, our second-generation NS5A inhibitor. As a potential cornerstone compound in genotype 1b targeted regimens, we are evaluating ACH-3102 in combination with our macrocyclic NS3/4A protease inhibitor, ACH-2684, and look forward to initiating future clinical trials for broader HCV treatment evaluating ACH-3102 in combination with our NS5B nucleotide polymerase inhibitor, ACH-3422, which is poised to enter Phase 1 trials.”

Oral Presentation Details
Session: Late Breaker Oral Presentation
Title: SVR4 results for the combination of ACH-3102 and sovaprevir, with ribavirin, in subjects with genotype 1 chronic hepatitis C infection.
Abstract: LB6
Presenter: David Apelian, M.D.
Date: Friday, March 14, 2014

Session: Concurrent Session
Title: ACH-3102 and ribavirin in genotype-1b hepatitis C patients: Confirmation of the high barrier to viral breakthrough in genotype-1b HCV.
Abstract: 437
Presenter: Mingjun Huang, Ph.D.
Date: Friday, March 14, 2014

e-Poster Presentation
Title: A single direct-acting anti-viral agent, ACH-3102, with ribavirin, is able to achieve a robust anti-viral response in subjects with genotype 1b chronic hepatitis C infection.
Authors: A. Muir, R. Brennan, et al.
Abstract: 625

Reprints of the oral presentation slides and poster will be accessible from the Achillion website at http://www.achillion.com.

About Achillion Pharmaceuticals

Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. Achillion’s discovery, clinical development, and commercial teams have advanced multiple novel product candidates with proven mechanisms of action into studies and toward the market. Achillion is focused on solutions for the most challenging problems in infectious disease including HCV and resistant bacterial infections. For more information on Achillion Pharmaceuticals, please visit www.achillion.com or call 1-203-624-7000.

SOURCE: Achillion Pharmaceuticals